| Identification | Back Directory | [Name]
1-Piperazinehexanamide, 4-[6,7-dimethoxy-4-[[1-(phenylmethyl)-4-piperidinyl]amino]-2-quinazolinyl]-N-hydroxy- | [CAS]
2630989-02-3 | [Synonyms]
HDAC1/6-IN-1
1-Piperazinehexanamide, 4-[6,7-dimethoxy-4-[[1-(phenylmethyl)-4-piperidinyl]amino]-2-quinazolinyl]-N-hydroxy- | [Molecular Formula]
C32H45N7O4 | [MOL File]
2630989-02-3.mol | [Molecular Weight]
591.74 |
| Hazard Information | Back Directory | [Uses]
HDAC1/6-IN-1 (compound D7) is a potent multitarget inhibitor of GLP, HDAC6 and HDAC1, with IC50 values of 1.3, 13, and 89 nM, respectively. HDAC1/6-IN-1 can inhibit the methylation and deacetylation of H3K9 on protein level. HDAC1/6-IN-1 induces cancer cell apoptosis, G0/G1 cell cycle arrest, and blocks migration and invasion[1]. | [IC 50]
HDAC6: 13 nM (IC50); HDAC1: 89 nM (IC50) | [References]
[1] Zheng H, et al. Quinazoline-based hydroxamic acid derivatives as dual histone methylation and deacetylation inhibitors for potential anticancer agents. Bioorg Med Chem. 2022 Jan 1;53:116524. DOI:10.1016/j.bmc.2021.116524 |
|
|